Farringdon Capital’s ImmunityBio IBRX Stock Holding History

Farringdon Capital’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-14,316	Closed	-$28.3K	–	482
2025 Q4	$28.3K	Sell	14,316 -2,328	-14%	-$5.27K	0.01%	414
2025 Q3	$40.9K	Buy	+16,644	New	+$42.9K	0.01%	430

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Farringdon Capital's IBRX Position: Q1 2026 in Review

Farringdon Capital sold out of ImmunityBio (IBRX) in Q1 2026, closing a stake of 14,316 shares — an estimated $28.3K sold.

Farringdon Capital first reported a position in IBRX in Q3 2025 and held it in 2 quarters. The position peaked at $40.9K in Q3 2025. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

Farringdon Capital reported no remaining ImmunityBio position as of Q1 2026 after selling out during the quarter.
Farringdon Capital sold 14,316 ImmunityBio shares in Q1 2026, an estimated $28.3K.
Farringdon Capital first reported a position in ImmunityBio in Q3 2025 and held it in 2 quarters.
Farringdon Capital's ImmunityBio position peaked at $40.9K in Q3 2025.
386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Farringdon Capital's 13F filing for Q1 2026, filed 15 May 2026.